Skip to main
PTHS

PTHS Stock Forecast & Price Target

PTHS Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Pelthos Therapeutics is in a very strong financial position, with $24 million in cash, access to additional funds, and three FDA-approved products in its commercial portfolio. With Zelsuvmi quickly becoming the market leader in the treatment of MC and strong adoption and utilization, Pelthos is well-positioned for success in the biopharmaceutical market. The company's focus on both commercial operations and research and development adds diversity to its revenue streams, and its solid IP protection and partnership with Horizon add stability to its financials. Overall, Pelthos has the potential for significant growth and a bright future ahead.

Bears say

Pelthos Therapeutics is experiencing robust growth with record product revenue and strong performance of Zelsuvmi marked by high prescriber adoption, improved access, and positive real-world feedback. However, a limited commercial adoption for Ycanth, high lesion burden subsets, and procedure limitations for dermatologists pose challenges. In the near-term, the focus is on Zelsuvmi launch execution, but potential future indications across dermatology offer potential for continued growth.

PTHS has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pelthos Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pelthos Therapeutics Inc (PTHS) Forecast

Analysts have given PTHS a Buy based on their latest research and market trends.

According to 6 analysts, PTHS has a Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $54.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $54.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pelthos Therapeutics Inc (PTHS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.